{"id":"NCT01514240","sponsor":"AstraZeneca","briefTitle":"Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan","officialTitle":"A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safety of D9421-C 9 mg Versus Mesalazine 3 g in Patients With Active Crohn's Disease (CD) in Japan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2012-01-23","resultsPosted":"2016-10-31","lastUpdate":"2016-10-31"},"enrollment":123,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"D9421-C capsule 3 mg","otherNames":[]},{"type":"DRUG","name":"Mesalazine tablets","otherNames":[]}],"arms":[{"label":"D9421-C","type":"EXPERIMENTAL"},{"label":"Mesalazine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region and/or ascending colon as defined by a score of 180-400 on the Crohn's Disease Activity Index (CDAI) by assessment of the remission after 8-week treatment defined by a CDAI score of â‰¤ 150.","primaryOutcome":{"measure":"Remission After 8-week of Treatment","timeFrame":"8 Week","effectByArm":[{"arm":"D9421-C 9mg + Mesalazine Placebo","deltaMin":17,"sd":null},{"arm":"Mesalazine 3g + D9421-C Placebo","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.526"}]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":25,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":56},"commonTop":["Nasopharyngitis","Crohn's disease","Vomiting","Pharyngitis","Headache"]}}